NEW YORK (GenomeWeb News) – Proteome Sciences and Millipore jointly announced today that they will collaborate on the development of multiplex immunoassays for Alzheimer's disease research.
Under terms of the deal, Millipore will develop the immunoassays on the Luminex platform to measure Proteome Sciences' Alzheimer's disease biomarkers. Billerica, Mass.-based Millipore will have exclusive rights to develop and sell Luminex bead-based panels for Alzheimer's research as well as other cognitive function disorders.
Cobham, UK-based Proteome Sciences retains all rights to clinical applications of the biomarkers. The firm has identified these biomarkers through a collaboration with the Institute of Psychiatry at Kings College, London.
"By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits."
Financial terms of the alliance were not disclosed.